Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer

Shiota Masaki; Yokomizo Akira; Takeuchi Ario; Kiyoshima Keijiro; Inokuchi Junichi; Tatsugami Katsunori; Naito Seiji

首页> 外文期刊>Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer >Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer

【24h】

Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer

机译：多西他赛化疗对去势抵抗性前列腺癌患者发热性中性粒细胞减少的危险因素

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Docetaxel is a standard therapy for patients with castration-resistant prostate cancer (CRPC). However, docetaxel-associated adverse events (AEs) such as febrile neutropenia (FN) can impair quality of life and may become life-threatening. In this study, we clarified the AEs and risk factors associated with FN in clinical settings.

机译：多西他赛是去势抵抗性前列腺癌（CRPC）患者的标准疗法。但是，与多西他赛相关的不良事件（AE），例如发热性中性粒细胞减少症（FN），可能会损害生活质量，并可能危及生命。在这项研究中，我们阐明了临床环境中与FN相关的AE和危险因素。

著录项

来源
《Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer》 |2014年第12期|共8页
作者
Shiota Masaki; Yokomizo Akira; Takeuchi Ario; Kiyoshima Keijiro; Inokuchi Junichi; Tatsugami Katsunori; Naito Seiji;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类护理学;
关键词
Castration-resistant prostate cancer; Docetaxel; Lymphopenia; Febrile neutropenia; Risk factor;

机译：去势抵抗性前列腺癌;多西他赛;淋巴细胞减少;发热性中性粒细胞减少;危险因素;

相似文献

外文文献
中文文献
专利

1. Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer [J] . Shiota Masaki, Yokomizo Akira, Takeuchi Ario, Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer . 2014,第12期

机译：多西他赛化疗对去势抵抗性前列腺癌患者发热性中性粒细胞减少的危险因素
2. Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy [J] . Shimpei Yamashita, Yasuo Kohjimoto, Takashi Iguchi, BMC Urology . 2016,第1期

机译：接受多西他赛化疗的去势抵抗性前列腺癌患者的预后因素和危险分层
3. 7020 Performance status and interval from first-line docetaxel-based chemotherapy to progression are significant prognostic factors in patients with castration-resistant prostate cancer receiving second-line chemotherapy [J] . Y.Loriot, C.Massard, M.Gross-Goupil, European Journal of Cancer Supplements . 2009,第2期

机译：7020年状态，从多西他赛一线化疗到进展的间隔时间是去势抵抗性前列腺癌接受二线化疗的患者的重要预后因素
4. Incidence and Risk Factors of Anemia in Breast Cancer Patients having Chemotherapy in Dr. Moewardi Hospital [C] . Wiwik Ekorinawati, Ambar Mudigdo, Brian Wasita International Conference on Sport Science, Health, and Physical Education . 2019

机译：在Moewardi医院博士中患有化疗的乳腺癌患者中贫血患者的发病率和危险因素
5. Effects of primary prophylaxis of neutropenia on outcomes, utilization and expenditures for elderly breast cancer patients receiving chemotherapy. [D] . Rajan, Suja S. 2009

机译：一级预防中性粒细胞减少对老年接受化疗的乳腺癌患者的结局，利用和支出的影响。
6. Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy [O] . Shimpei Yamashita, Yasuo Kohjimoto, Takashi Iguchi, 2016

机译：接受多西他赛化疗的去势抵抗性前列腺癌患者的预后因素和危险分层
7. Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer [O] . Masaki Shiota, Akira Yokomizo, Ario Takeuchi, 2014

机译：发热中性粒细胞减少症患者抗紫杉醇化疗抗阉割前列腺癌的危险因素

Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer

摘要

著录项

相似文献

相关主题

期刊订阅